IV

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

Retrieved on: 
Friday, October 6, 2023
Psoriatic arthritis, Ankylosing spondylitis, Rheumatology Research Foundation, AS, Rheumatology, Swedish Medical Center (Colorado), University, Novartis, Medicine, US Foods, EAST, FDA, Swedish Health Services, IV, Research, University of Washington School of Medicine, Patient, Pharmaceutical industry, Secukinumab, Immunology

Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.

Key Points: 
  • Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.
  • The IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.1 The new IV administration option will be available in Q4 of 2023.
  • "The approval of Cosentyx as an IV formulation is an important milestone for patients because it expands the treatment options available to them with a different mechanism of action than existing biologic IV therapies, along with the comfort and familiarity of an established treatment."
  • "At Novartis, we are committed to ensuring healthcare providers and patients have treatment options available to meet their unique needs.

Top Reno, NV, Plastic Surgeon Dr. Erez Dayan Opens EMET Medical Wellness Clinic: A Holistic Approach to Health

Retrieved on: 
Thursday, October 5, 2023
Health, Multimedia, RENO, Breast, Regenerative medicine, Harvard University, IV, Patient, PRP, Injection, Face, Quality of life, Dentistry, Medical device

RENO, Nev., Oct. 5, 2023 /PRNewswire-PRWeb/ -- Dr. Erez Dayan, a leading authority in the field of regenerative medicine and plastic surgery, is excited to introduce a new and comprehensive range of services that address the unique needs of each patient. He is proud to share the grand opening of EMET Medical Wellness, a state-of-the-art center that aims to revolutionize the way health and wellness is approached, by helping patients walk the path of self-care and improved quality of life. Headed up by Dr. Dayan, who is a Harvard-educated and fellowship-trained plastic and reconstructive surgeon, EMET Medical Wellness provides treatment, therapeutic protocols and wellness plans tailored completely to individual unique needs, backed by expert knowledge and cutting-edge science. Medical weight loss, PRP injections, IV drip therapy and hyperbaric therapy are just a few of the ways the team at EMET Medical Wellness can work to support wellness goals. Dr. Dayan believes that true wellness encompasses more than just physical appearance and that a deeper sense of well-being can be achieved through a personalized approach to healthcare. The EMET Medical Wellness team has curated the best available treatments and technology to promote wellness from all over the country and abroad over the past 4 years. They are excited to introduce this top wellness center offering, not previously available in Nevada.

Key Points: 
  • Headed up by Dr. Dayan, who is a Harvard-educated and fellowship-trained plastic and reconstructive surgeon, EMET Medical Wellness provides treatment, therapeutic protocols and wellness plans tailored completely to individual unique needs, backed by expert knowledge and cutting-edge science.
  • Medical weight loss , PRP injections, IV drip therapy and hyperbaric therapy are just a few of the ways the team at EMET Medical Wellness can work to support wellness goals.
  • At EMET Medical Wellness, the highly credentialed care team works closely with patients, taking into consideration various lifestyle, health, and wellness factors to tailor unique care plans.
  • For those seeking a comprehensive approach to health and wellness, EMET Medical Wellness is the ultimate destination.

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Retrieved on: 
Thursday, October 5, 2023
Consultant, Hospital, Research, Risk, Toxicity, Vancomycin, S. aureus, IV, Biocomposite, Infection, Surgeon, Osteomyelitis, PD, Synovial fluid, Patient, Antibiotics, Poultry farming, Pharmaceutical industry

Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.

Key Points: 
  • Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.
  • Dr. Yvonne Achermann and I look forward to speaking on the merits of local antibiotic delivery in managing infection at this upcoming industry meeting."
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "EBJIS is an important annual event at which surgeons, podiatrists and scientists catch up on the latest information in the field of bone and joint infection treatment.
  • Details of Biocomposites' symposium and the abstract accepted at the EBJIS Annual Meeting are listed below:
    Presenters: Mr.

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Retrieved on: 
Thursday, October 5, 2023
Consultant, Hospital, Research, Risk, Toxicity, Vancomycin, S. aureus, IV, Biocomposite, Infection, Surgeon, Osteomyelitis, PD, Synovial fluid, Patient, Antibiotics, Poultry farming, Pharmaceutical industry

Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.

Key Points: 
  • Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.
  • Dr. Yvonne Achermann and I look forward to speaking on the merits of local antibiotic delivery in managing infection at this upcoming industry meeting."
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "EBJIS is an important annual event at which surgeons, podiatrists and scientists catch up on the latest information in the field of bone and joint infection treatment.
  • Details of Biocomposites' symposium and the abstract accepted at the EBJIS Annual Meeting are listed below:
    Presenters: Mr.

FranDevCo Announces IV Nutrition as Newest Partnering Brand, Solidifying an Impressive Q3

Retrieved on: 
Wednesday, October 4, 2023
Partnership, IV, Prevalence, Education, Quality of life, Nutrient, Nutritional science, USD, Conditional sentence, Growth, Health, Pharmaceutical industry, Medical device

CHARLOTTE, N.C., Oct. 4, 2023 /PRNewswire/ -- FranDevCo, a franchise development company specializing in emerging and growth-oriented franchise brands, announces a new partnership with intravenous hydration therapy company, IV Nutrition. The brand offers specialized IV and injection nutrient therapy that can give the body the important nutrients it needs to function at its best.

Key Points: 
  • CHARLOTTE, N.C., Oct. 4, 2023 /PRNewswire/ -- FranDevCo, a franchise development company specializing in emerging and growth-oriented franchise brands, announces a new partnership with intravenous hydration therapy company, IV Nutrition.
  • IV Nutrition was founded in 2017 by Dr. Tara Zeller and Dr. Jason Fechter.
  • "Partnering with IV Nutrition will help us become part of a larger mission by helping the team expand and provide care for customer's unique health.
  • "Partnering with FranDevCo means we can deliver the healing powers of IV Nutrition to more people at a faster rate," said IV Nutrition Founder Dr. Tara Zeller.

Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis Report 2023-2029: Focus on Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 4, 2023
Health, Pharmaceutical, Infusion, System, Fresenius (company), IV, Pump, Injury, Ageing, Research, BD (company), National League Championship Series, Infusion pump, Timeline of the COVID-19 pandemic in the United States, PCA, Hospital, Risk, Growth, COVID19, Medical device, Pharmaceutical industry

The "Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis 2023-2029 MedSuite Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Infusion Therapy Market Size, Share & COVID19 Impact Analysis 2023-2029 MedSuite Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks & Blood Transfusion Sets" report has been added to ResearchAndMarkets.com's offering.
  • Our complete report suite on the European infusion therapy devices market encompasses six distinct categories: infusion pumps, intravenous (IV) sets, needleless connectors (NLCs), IV filters, stopcocks, and blood transfusion sets.
  • Market Share Insights into Infusion Therapy:
    In the year 2022, B. Braun emerged as the frontrunner in the European infusion therapy device market.
  • Blood Transfusion Set Market - MedCore - The chapter provides an overview of the Blood Transfusion Set market.

Leidos receives extension on LAMS system for additional Artemis missions

Retrieved on: 
Tuesday, October 3, 2023
LDOS, Environmental control system, IV, Life-support system, Risk, Artemis 4, Research, Moon, Kennedy Space Center, NASA, Annual report, LAMS, Artemis, ORION, Spacecraft, NYSE, Communications satellite, ECLSS, Leidos

HUNTSVILLE, Ala., Oct. 3, 2023 /PRNewswire/ -- Leidos (NYSE: LDOS) announced today that it received a contract award from NASA extending production of the company's Laser Air Monitoring System (LAMS) for Artemis IV and V missions.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 3, 2023 /PRNewswire/ -- Leidos (NYSE: LDOS) announced today that it received a contract award from NASA extending production of the company's Laser Air Monitoring System (LAMS) for Artemis IV and V missions.
  • The total contract value of $37.8 million includes the completed fabrication of LAMS for the Artemis III, IV and V missions to the moon.
  • "This extension reaffirms the importance of LAMS to the ORION Program and our commitment to NASA's mission," said Leidos Space Division Manager for the Dynetics Group Robert Wright.
  • "We have a talented team of committed engineers working on this exciting NASA program, and they are ready to build and deliver nine LAMS units for both Artemis IV and V missions," said Trista Niemann, Leidos LAMS Program Manager.

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Retrieved on: 
Monday, October 2, 2023
Taste, DMT, PD, IV, OTF, Permeability, Entrepreneurship, Safety, Pharmaceutical industry, Pharmacokinetics

“We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our proprietary OTF formulation of DMT,” said Florian Brand, CEO and Co-Founder of atai.

Key Points: 
  • “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our proprietary OTF formulation of DMT,” said Florian Brand, CEO and Co-Founder of atai.
  • The study enrolled a total of 74 healthy participants across three parts.
  • The company now plans to progress VLS-01 into a Phase 1b study in healthy participants.
  • The company has submitted a protocol to regulatory authorities and expects to enroll the first participant in a Phase 1b study in 1H 2024.

Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)

Retrieved on: 
Monday, October 2, 2023
Health, FDA, Hospitals, Surgery, Managed Care, Pharmaceutical, Biotechnology, Priority review, Centers for Medicare & Medicaid Services, CMS, NTAP, IV, QIDP, Food, Candidiasis, Fungemia, Medicare, Hospital, Patient, Physician, Injection, Echinocandin, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Pharmaceutical industry, Health insurance, Melinta Therapeutics

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).

Key Points: 
  • Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).
  • “These two important milestones will help facilitate access to this innovative treatment option in both inpatient and outpatient settings.
  • Last year, Melinta acquired the exclusive rights to commercialize REZZAYO in the U.S. from Cidara Therapeutics.
  • “This is another opportunity for Melinta to deliver on our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses.”

The DRIPBaR Launched in Trophy Club, TX on August 30th!

Retrieved on: 
Monday, October 2, 2023
IV, Low-level laser therapy, IM, Justin, Danny Deever, Health, Hunting

TROPHY CLUB, Texas, Oct. 2, 2023 /PRNewswire-PRWeb/ -- October 2023: The DRIPBaR proudly announces the successful launch of its newest location in Trophy Club, TX. With doors officially open as of August 30th, 2023, the Trophy Club community can now experience all of the standard DRIPBaR services, including IV drips and IM shots. This particular location will also offer a suite of additional wellness services – including Red Light Therapy, Botox/Dysport, and Mobile IV services.

Key Points: 
  • With doors officially open as of August 30th, 2023, the Trophy Club community can now experience all of the standard DRIPBaR services, including IV drips and IM shots.
  • To celebrate their arrival, The DRIPBaR Trophy Club is offering 50% off your first IV drip.
  • Jamie Deevers is the proud proprietor and operator of The DRIPBaR Trophy Club .
  • The DRIPBaR Trophy Club is thrilled to serve the local community, as well as the surrounding areas of Roanoke, Westlake, Southlake, Argyle, Northlake, Justin, and Keller, TX.